Digitalis Ventures

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

Aviceda Therapeutics is a late-stage pre-clinical biotechnology company focused on developing innovative therapies for glyco-immune diseases. The company leverages glycobiology and a proprietary cell-based high-throughput screening platform to create next-generation immunomodulators that target the innate immune system and address chronic non-resolving inflammation. Aviceda’s therapeutic pipeline includes a range of products aimed at various conditions, such as dry eye, diabetic retinopathy, retinoblastoma, and other diseases in the fields of oncology, neurology, and fibrosis. The company’s approach combines advanced biological insights with cutting-edge nanoparticle technology, enabling the development of targeted treatments designed to improve patient outcomes.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

Terray Therapeutics, founded in 2018 and based in Pasadena, California, is a biotechnology company dedicated to advancing drug discovery for intractable diseases. It operates a unique platform that combines experimentation and computation to efficiently explore chemical space, generating precise data through rapid design-make-test-analyze cycles. The company employs artificial intelligence, synthetic chemistry, automation, and nanotechnology to create comprehensive datasets using ultra-dense microarray technology. These datasets systematically map biochemical interactions between small molecules and disease targets, enabling iterative cycles of virtual molecular design and experimentation that guide AI and machine learning models for predictive insights in drug discovery.

Reema Health is a technology startup focused on bridging the gaps between healthcare and social care. The company operates a healthcare platform that utilizes tech-enabled community guides to connect individuals with essential care and resources. By offering a personalized, community-based approach, Reema Health empowers users to identify specific actions needed to improve their behavioral health. This innovative platform aims to facilitate easier access to medical care and enhance the overall well-being of its users.

Judo Bio is a biotechnology company focused on developing precision therapeutics that target specific cell populations to treat genetic diseases. Utilizing an innovative receptor targeting approach, Judo Bio is building a pipeline of treatments designed to address both common and rare diseases. Currently, the company is operating in stealth mode, indicating a period of research and development prior to a public launch or disclosure of its initiatives.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

Elegen is a biotechnology company founded in 2017 and led by Dr. Matthew Hill, specializing in the development of microfluidic technology. The company focuses on creating innovative DNA synthesizers that enhance the engineering of entire genomes. By leveraging its advanced technology, Elegen aims to accelerate biomedical advancements and facilitate DNA sequence testing within the healthcare industry. Through its commitment to disrupting synthetic biology, Elegen is positioned to play a pivotal role in the future of genetic research and applications.

Alterome Therapeutics is a biotechnology company focused on precision oncology, specializing in the development of alteration-specific therapeutics aimed at treating cancer. By targeting high-value and validated oncogenic drivers, Alterome seeks to create innovative biopharmaceutical therapies that offer hope to individuals affected by cancer. The company's approach is centered on discovering and developing precise treatments that cater to the unique genetic alterations present in different cancer types, thereby enhancing the effectiveness of cancer therapies for healthcare providers and patients alike.

MoeGo is a developer of a business management platform tailored for the pet grooming community. The company's software facilitates appointment scheduling, optimizes transportation routes, and enhances online visibility for pet professionals. By streamlining these essential services, MoeGo enables pet grooming businesses to effectively engage with their customers and build trust, ultimately supporting their growth within the industry.

Gallant Therapeutics is an animal health biotechnology company developing allogeneic, "off-the-shelf" stem cell therapies from their stem cell platform. Gallant is also the leading provider of non-invasive stem cell banking during the spay or neuter process, opening the door to novel regenerative medical treatments formerly unavailable for non-human family members. Clinical studies demonstrate stem cell therapies help pets with a multitude of ailments, including osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis, among others. Gallant's first product helps to save cats that would die of chronic gingivostomatitis, with a robust pipeline in development for companion animals.

Gallant Pet, Inc. is a pet service company based in San Diego, California, that specializes in stem cell preservation services for pets. Founded in 2018 by Aaron Hirschhorn, the company collects and banks stem cells from tissue during routine spay or neuter procedures. Gallant Pet also provides a platelet-rich plasma (PRP) kit for treatment of dogs suffering from osteoarthritis or other musculoskeletal conditions. In addition to its preservation services, Gallant Pet is involved in clinical research to develop effective stem cell therapies for pets. The company's focus on retrieving and preserving regenerative cells allows pet owners to utilize their pets' young stem cells for potential treatments when needed.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Eden Brew is a food and beverage company focused on producing animal-free and precision-fermented milk and dairy products. The company aims to provide an environmentally sustainable alternative to traditional cow's milk, offering dairy products that are vegan-friendly and lactose-free. Using precision fermentation technology, Eden Brew creates milk that contains nature-identical proteins and nutrients, allowing consumers to enjoy the taste and nutritional benefits of dairy without the environmental impact associated with conventional dairy farming.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Companion creates technology that simplifies how owners interact with and train their dogs. Companion's proprietary technology communicates with dogs through audio, and 3D sensing systems detect and analyze the dog's movement and behaviors. With machine learning, it can adapt in real-time, calculating the best way to engage with a dog. Companion rewards the dog for desired behaviors such as sit, down, stay, and recall using positive reinforcement techniques and proprietary data and algorithms.

Switch Therapeutics is a biotechnology company founded in 2020 and based in San Francisco, California. The company focuses on revolutionizing RNA interference (RNAi) therapies by developing biomarker-gated genetic medicines. These innovative therapies utilize nucleic acid nanotechnology and RNAi science to target a variety of diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. Switch Therapeutics aims to provide healthcare providers with RNA molecules and therapies that can be activated selectively in specific cells, enhancing the precision of treatments for central nervous system diseases.

Onc.AI, Inc. is a technology company founded in 2020 and headquartered in San Carlos, California. It specializes in clinical oncology, utilizing advanced software that integrates genomics, proteomics, and radiomics to enhance oncology diagnostics. By employing deep learning techniques, Onc.AI aims to provide actionable insights that improve treatment outcomes for cancer patients. The company's innovative approach seeks to advance the field of oncology through the development of comprehensive data-driven solutions.

Bonum Therapeutics is a biotechnology company focused on developing protein-based drugs aimed at treating various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs capable of sensing their local environment and transitioning from an inactive to an active form. This innovative approach allows for the development of therapeutics that can be tailored to respond to specific conditions, thereby enhancing the potential for effective treatment of diseases that currently lack viable cures. In addition to cancer, Bonum Therapeutics also targets metabolic diseases, immunological disorders, and pain management.

Elemental Machines, Inc., founded in 2014 and based in Cambridge, Massachusetts, specializes in providing a smart lab platform designed to enhance laboratory operations in science-based industries. The company's innovative technology continuously monitors equipment and environmental variables, delivering data-driven insights that foster improved research, development, and manufacturing outcomes. By utilizing intelligent sensors, the platform visualizes the entire testing environment and issues alerts for any anomalous results, thereby ensuring experimental reproducibility. This capability allows clients to refine and accelerate their work across all phases of product innovation, ultimately leading to greater clarity, transparency, and consistency in laboratory processes.

Matchpoint Therapeutics is a biotechnology company focused on developing precision covalent medicines aimed at transforming the treatment of immune diseases and other serious illnesses. Utilizing its proprietary Advanced Covalent Exploration (ACE) platform, the company combines advanced chemoproteomics, machine learning, and the evolution of covalent chemistry libraries to enhance the discovery process. This innovative approach allows for deeper probing of the proteome to identify new binding sites on disease-causing proteins. Matchpoint is building an emerging pipeline of novel covalent medicines, with an initial emphasis on immunology.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Ness builds a credit card-first wedge into healthcare. It allows its user to earn rewards for healthy purchases and access exclusive perks to complement their lifestyle. It was established in 2021 and is based in New York, United States.

Eden Brew is a food and beverage company focused on producing animal-free and precision-fermented milk and dairy products. The company aims to provide an environmentally sustainable alternative to traditional cow's milk, offering dairy products that are vegan-friendly and lactose-free. Using precision fermentation technology, Eden Brew creates milk that contains nature-identical proteins and nutrients, allowing consumers to enjoy the taste and nutritional benefits of dairy without the environmental impact associated with conventional dairy farming.

Terray Therapeutics, founded in 2018 and based in Pasadena, California, is a biotechnology company dedicated to advancing drug discovery for intractable diseases. It operates a unique platform that combines experimentation and computation to efficiently explore chemical space, generating precise data through rapid design-make-test-analyze cycles. The company employs artificial intelligence, synthetic chemistry, automation, and nanotechnology to create comprehensive datasets using ultra-dense microarray technology. These datasets systematically map biochemical interactions between small molecules and disease targets, enabling iterative cycles of virtual molecular design and experimentation that guide AI and machine learning models for predictive insights in drug discovery.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.

Elegen is a biotechnology company founded in 2017 and led by Dr. Matthew Hill, specializing in the development of microfluidic technology. The company focuses on creating innovative DNA synthesizers that enhance the engineering of entire genomes. By leveraging its advanced technology, Elegen aims to accelerate biomedical advancements and facilitate DNA sequence testing within the healthcare industry. Through its commitment to disrupting synthetic biology, Elegen is positioned to play a pivotal role in the future of genetic research and applications.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

BIOMILQ is a women-owned start-up based in Durham, North Carolina, founded in 2020. The company specializes in producing nutritionally equivalent breastmilk using cultured human mammary cells. By leveraging a unique biomanufacturing platform, BIOMILQ aims to create bioauthentic human milk ingredients that support early-life nutrition. Its products are designed to provide a sustainable and nutritious alternative for mothers and caregivers, promoting immune, gut, and neurological development in infants. Through its patented technology, BIOMILQ seeks to empower families with options that mirror the benefits of natural breastmilk, enhancing infant health and nutrition.

Scout Bio, Inc. is a biotechnology company focused on advancing veterinary medicine through innovative therapies for chronic pet health conditions. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, the company specializes in developing one-time treatments utilizing veterinary biotechnology and gene therapy. Scout Bio's offerings include therapies for conditions such as anemia associated with chronic kidney disease in cats, as well as a range of small molecular drugs, protein therapies, and gene therapies. Employing adeno-associated viral vector technology, Scout Bio aims to transform veterinary care by providing effective protein and monoclonal antibody therapeutics delivered through single intra-muscular injections, thereby enhancing the quality of life for pets and supporting veterinary professionals.

Kingdom Supercultures is a Brooklyn-based company established in 2019 that specializes in developing and producing microbial cultures for the food industry. The company focuses on reassembling nature's microbes into innovative combinations, allowing food manufacturers to create new varieties of food with enhanced benefits. Their product line includes Koji, a traditional Japanese ingredient used in miso, sake, and soy sauce, as well as microbial cultures for fermented sodas, beers, and plant-based dairy alternatives. Kingdom Supercultures employs an automated scientific platform that features a comprehensive biobank of Generally Recognized As Safe (GRAS) microbial strains and utilizes advanced algorithms to predict and assemble microbial communities. By providing functional ingredients and biopreservatives, the company aims to support healthy and sustainable food development across various industries, including food, beverage, personal care, and beauty.

UnifiHealth is reimagining how health benefits are built and delivered to small businesses. The company was founded in 2019 and based in Columbus, Ohio.

PetMedix Ltd is a veterinary biopharmaceutical company based in Hinxton, United Kingdom, that specializes in therapeutic drug discovery for pets. Founded in 2017, the company utilizes advanced scientific techniques to develop innovative antibody therapies aimed at improving the health and well-being of companion animals. PetMedix has created specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce therapeutic-quality antibodies tailored for pets. This approach allows for the generation of a diverse repertoire of antibodies that mirrors the immune systems of companion animals, enabling veterinarians to administer safe and effective monoclonal antibody treatments. By applying over thirty years of expertise in human drug development to veterinary medicine, PetMedix is dedicated to enhancing the quality of life for pets through cutting-edge therapies.

Cayaba Care is a maternal health company focused on providing comprehensive support to medium and high-risk women throughout their pregnancy and postpartum journeys. The company employs a multidisciplinary approach, utilizing Maternity Navigators who are also certified doulas, to partner with members and enhance birth outcomes. Cayaba Care's services address a range of pregnancy-related concerns, including symptom relief, mental health support, breastfeeding assistance, and postpartum follow-up. By offering both virtual and in-person care, the company aims to alleviate stress and anxiety associated with pregnancy, ensuring that women experience a healthy and safe journey. Cayaba Care collaborates with commercial and Medicaid plans to implement standard and value-based care contracts, ultimately improving care quality and patient experience while achieving significant cost savings.

Terray Therapeutics, founded in 2018 and based in Pasadena, California, is a biotechnology company dedicated to advancing drug discovery for intractable diseases. It operates a unique platform that combines experimentation and computation to efficiently explore chemical space, generating precise data through rapid design-make-test-analyze cycles. The company employs artificial intelligence, synthetic chemistry, automation, and nanotechnology to create comprehensive datasets using ultra-dense microarray technology. These datasets systematically map biochemical interactions between small molecules and disease targets, enabling iterative cycles of virtual molecular design and experimentation that guide AI and machine learning models for predictive insights in drug discovery.

AnimalBiome specializes in personalized nutrition services that focus on enhancing the gut health of dogs and cats through microbiome science. The company offers microbiome tests that assess the unique gut microbiota of individual pets, providing insights that inform tailored nutrition recommendations. Additionally, AnimalBiome develops restorative supplements made from material sourced from healthy animals, allowing for the introduction of beneficial microbes to help restore balance in the gut microbiome. By leveraging advanced diagnostic tools, including DNA sequencing, AnimalBiome enables pet owners to better understand their pets' gut health, ultimately contributing to improved well-being and a healthier lifestyle for their animals.

Aunt Bertha is a Public Benefit Corporation that operates a social services search and referrals software platform designed to help individuals locate various welfare programs. Founded in 2010 and based in Austin, Texas, the company provides users with access to resources related to food, shelter, healthcare, employment, and financial assistance. The platform facilitates connections between those in need and available support services, streamlining the process of finding and applying for government and charitable programs. Aunt Bertha serves a diverse range of sectors, including healthcare, education, government, and child welfare, effectively reducing the administrative costs associated with social service program management by enabling online applications.

Code Ocean, Inc. operates a cloud-based platform that facilitates the sharing, discovery, and execution of code and data for researchers and developers. Founded in 2015 and based in New York, the company provides an open access environment where users can publish and run code associated with academic research without the need for local software installation. Its platform supports the entire research workflow, from project inception to publication, by allowing researchers to deposit their code, data, and necessary dependencies into self-contained compute capsules. This approach enhances reproducibility and collaboration in research, empowering users to transparently access algorithms and methodologies alongside their data. Code Ocean caters to researchers, institutions, and publishers, striving to standardize research workflows and promote the reuse of computational research.

Ansel Health is a company that develops a health insurance platform designed to improve employee benefits for employers through a straightforward supplemental health benefits plan. The platform provides insurance services that offer financial support in the form of cash payments to individuals diagnosed with various covered conditions, including those related to COVID-19. This support aims to help mitigate the financial challenges associated with serious health issues, facilitating a smoother recovery process for affected individuals.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, that focuses on developing gene therapies to enhance health and extend the lifespans of dogs and other domesticated animals. Founded in 2017, the company utilizes innovative approaches derived from research at the Wyss Institute at Harvard Medical School to create anti-aging therapies and address age-related diseases. By introducing new DNA instructions into the bodies of pets, Rejuvenate Bio aims to offer solutions for chronic conditions and improve overall well-being. The company's gene therapy pipeline is designed to target specific diseases and leverage clinically validated gene targets to ensure effective and lasting results.

SeQure DX is a biotechnology company specializing in genomics diagnostics for CRISPR-based gene editing therapies. It develops technologies that identify potential off-target sites prior to therapy initiation, ensuring comprehensive confirmation of actual edits. This enables safer and more effective gene editing therapeutics development, benefiting both researchers and patients.

UnifiHealth is reimagining how health benefits are built and delivered to small businesses. The company was founded in 2019 and based in Columbus, Ohio.

Onc.AI, Inc. is a technology company founded in 2020 and headquartered in San Carlos, California. It specializes in clinical oncology, utilizing advanced software that integrates genomics, proteomics, and radiomics to enhance oncology diagnostics. By employing deep learning techniques, Onc.AI aims to provide actionable insights that improve treatment outcomes for cancer patients. The company's innovative approach seeks to advance the field of oncology through the development of comprehensive data-driven solutions.

Nuperfect is a company based in Shenzhen, China, that specializes in the design and development of invisible orthosis devices, particularly for teeth correction. Founded in 2019, Nuperfect creates custom braces tailored to individual needs using a combination of three-dimensional digital dental models, artificial intelligence, cloud computing, and 3D printing technology. The company also offers offline dental scanning services and home dental mold tools to facilitate accurate teeth data collection. Through its online portal, Nuperfect provides users with personalized orthodontic solutions and precision-engineered invisible correction braces, enhancing the teeth-straightening experience.

Ansel Health is a company that develops a health insurance platform designed to improve employee benefits for employers through a straightforward supplemental health benefits plan. The platform provides insurance services that offer financial support in the form of cash payments to individuals diagnosed with various covered conditions, including those related to COVID-19. This support aims to help mitigate the financial challenges associated with serious health issues, facilitating a smoother recovery process for affected individuals.

Smalls is a direct-to-consumer pet food company based in New York that specializes in producing human-grade, fresh food for cats. Founded in 2017 by co-founders Matt Michaelson and Calvin Hughes, the company offers a range of cat food options, including chicken, beef, turkey, and duck, as well as freeze-dried variants. Each product is crafted using fresh meat and a small amount of green vegetables, gently cooked to preserve nutrients and moisture. Smalls provides customized meal kits tailored to meet the specific nutritional needs of cats, ensuring that pet owners can conveniently access healthy and fresh food delivered directly to their homes.

Base5 Genomics, Inc. is a biotechnology firm focused on developing sequencing solutions aimed at enhancing personalized care. Founded in 2018 and headquartered in Palo Alto, California, the company specializes in revealing the full genomic diversity in humans and other organisms. Its technologies are particularly significant in the fields of cancer biology, DNA damage and repair, genome organization, and gene regulation. By providing insights into genetic makeup, Base5 Genomics enables the medical community to advance personalized medicine, facilitating tailored treatments that meet the specific needs of patients.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.

Kenzen, Inc. is a health technology company that specializes in developing wearable solutions for health and performance monitoring. Its flagship product, the Kenzen ECHO, is a wireless smart patch designed to provide real-time monitoring of vital signs and physiological data, with a focus on preventing injuries related to heat stress, fatigue, and over-exertion in industrial settings. The ECHO system includes a mobile application that delivers personalized health insights and alerts, ensuring that workers and their supervisors can take proactive measures to enhance safety and productivity. Incorporated in 2014 and based in New York, Kenzen sells its products through various distributors, resellers, and retail locations, aiming to harness physiological data to improve workforce safety and well-being.

Scratch is a financial technology company that specializes in providing payment processing, patient financing, and communication tools tailored for veterinary and medical practices. With its platform utilized by approximately half of all U.S. veterinary clinics, Scratch facilitates seamless interactions and transactions between practices and their clients, both in-person and remotely. The company's patient financing solution offers quick access to guaranteed payment options, allowing patients and pet owners to secure funding for medical care within 60 seconds. Additionally, Scratch's payment processing tools are designed to integrate with leading practice management systems, enhancing the checkout experience for both patients and practices.

The Mighty is a digital health community designed to empower and connect individuals who are facing health challenges and disabilities. The platform provides a space for users to share stories and videos of their personal experiences with disability, disease, and mental illness. This sharing enables users to connect with others who have similar experiences, fostering a supportive environment that promotes positive energy and mutual understanding.

Aunt Bertha is a Public Benefit Corporation that operates a social services search and referrals software platform designed to help individuals locate various welfare programs. Founded in 2010 and based in Austin, Texas, the company provides users with access to resources related to food, shelter, healthcare, employment, and financial assistance. The platform facilitates connections between those in need and available support services, streamlining the process of finding and applying for government and charitable programs. Aunt Bertha serves a diverse range of sectors, including healthcare, education, government, and child welfare, effectively reducing the administrative costs associated with social service program management by enabling online applications.

Code Ocean, Inc. operates a cloud-based platform that facilitates the sharing, discovery, and execution of code and data for researchers and developers. Founded in 2015 and based in New York, the company provides an open access environment where users can publish and run code associated with academic research without the need for local software installation. Its platform supports the entire research workflow, from project inception to publication, by allowing researchers to deposit their code, data, and necessary dependencies into self-contained compute capsules. This approach enhances reproducibility and collaboration in research, empowering users to transparently access algorithms and methodologies alongside their data. Code Ocean caters to researchers, institutions, and publishers, striving to standardize research workflows and promote the reuse of computational research.

Pawp, Inc. is a digital health clinic and telehealth platform founded in 2020 and based in New York, New York. The company focuses on providing pet owners with 24/7 access to licensed veterinary professionals, enabling them to manage their pets' health effectively. Pawp's services aim to reduce unnecessary veterinary visits by offering expert consultations online, thereby lowering costs for pet owners. Additionally, the company provides a pet emergency fund of $3,000 per year, acting as a financial safety net for unforeseen veterinary expenses. By combining access to veterinary care and emergency funding, Pawp empowers pet owners to make informed health decisions for their pets.

Scout Bio, Inc. is a biotechnology company focused on advancing veterinary medicine through innovative therapies for chronic pet health conditions. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, the company specializes in developing one-time treatments utilizing veterinary biotechnology and gene therapy. Scout Bio's offerings include therapies for conditions such as anemia associated with chronic kidney disease in cats, as well as a range of small molecular drugs, protein therapies, and gene therapies. Employing adeno-associated viral vector technology, Scout Bio aims to transform veterinary care by providing effective protein and monoclonal antibody therapeutics delivered through single intra-muscular injections, thereby enhancing the quality of life for pets and supporting veterinary professionals.

Terray Therapeutics, founded in 2018 and based in Pasadena, California, is a biotechnology company dedicated to advancing drug discovery for intractable diseases. It operates a unique platform that combines experimentation and computation to efficiently explore chemical space, generating precise data through rapid design-make-test-analyze cycles. The company employs artificial intelligence, synthetic chemistry, automation, and nanotechnology to create comprehensive datasets using ultra-dense microarray technology. These datasets systematically map biochemical interactions between small molecules and disease targets, enabling iterative cycles of virtual molecular design and experimentation that guide AI and machine learning models for predictive insights in drug discovery.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

PetMedix Ltd is a veterinary biopharmaceutical company based in Hinxton, United Kingdom, that specializes in therapeutic drug discovery for pets. Founded in 2017, the company utilizes advanced scientific techniques to develop innovative antibody therapies aimed at improving the health and well-being of companion animals. PetMedix has created specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce therapeutic-quality antibodies tailored for pets. This approach allows for the generation of a diverse repertoire of antibodies that mirrors the immune systems of companion animals, enabling veterinarians to administer safe and effective monoclonal antibody treatments. By applying over thirty years of expertise in human drug development to veterinary medicine, PetMedix is dedicated to enhancing the quality of life for pets through cutting-edge therapies.

SchoolCare is a digital health platform that provides free health technology to K-12 public schools, enabling school nurses to deliver effective care and enhance student safety. The company aims to create a unified health record for every family by leveraging pediatric health data within the extensive K-12 school system, which serves as a vital public health infrastructure. SchoolCare's platform captures essential student medical information, including charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. By addressing gaps in traditional care coordination, SchoolCare ensures that crucial care instructions reach school nurses, thereby reducing the risk of inconsistent post-discharge care. Through its innovative approach, SchoolCare seeks to improve health outcomes for children and streamline public school health programs across the United States.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.

MollyBox is a subscription-based e-commerce platform based in Shanghai, China, serving pet owners with a focus on cat products. Founded in 2015 by Yifu Sun and Yi Ju, the company provides themed monthly boxes containing natural meal products and toys for cats. Customers have the flexibility to subscribe for monthly or annual deliveries, as well as the option to purchase individual items. By curating a selection of pet foods and supplies, MollyBox aims to simplify the shopping experience for cat owners while ensuring high-quality, enjoyable products for their pets.

Girihlet Inc. is a genetic-sequencing company based in Oakland, California, founded in 2012. It specializes in providing rapid and accurate deep sequencing services, focusing on T cell receptor profiling and mitochondrial DNA analysis. Utilizing novel, bias-free methods, Girihlet aims to harness these genomic insights as biomarkers for diagnostics across various disorders, particularly those related to T-cell-driven autoimmune conditions. The company employs advanced sequencing technologies combined with machine learning to decode immune responses, thereby informing appropriate therapeutic strategies. Through its innovative approach, Girihlet seeks to enhance diagnostic capabilities and support researchers in advancing basic research in immunology.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, that focuses on developing gene therapies to enhance health and extend the lifespans of dogs and other domesticated animals. Founded in 2017, the company utilizes innovative approaches derived from research at the Wyss Institute at Harvard Medical School to create anti-aging therapies and address age-related diseases. By introducing new DNA instructions into the bodies of pets, Rejuvenate Bio aims to offer solutions for chronic conditions and improve overall well-being. The company's gene therapy pipeline is designed to target specific diseases and leverage clinically validated gene targets to ensure effective and lasting results.

Scratch is a financial technology company that specializes in providing payment processing, patient financing, and communication tools tailored for veterinary and medical practices. With its platform utilized by approximately half of all U.S. veterinary clinics, Scratch facilitates seamless interactions and transactions between practices and their clients, both in-person and remotely. The company's patient financing solution offers quick access to guaranteed payment options, allowing patients and pet owners to secure funding for medical care within 60 seconds. Additionally, Scratch's payment processing tools are designed to integrate with leading practice management systems, enhancing the checkout experience for both patients and practices.

Kenzen, Inc. is a health technology company that specializes in developing wearable solutions for health and performance monitoring. Its flagship product, the Kenzen ECHO, is a wireless smart patch designed to provide real-time monitoring of vital signs and physiological data, with a focus on preventing injuries related to heat stress, fatigue, and over-exertion in industrial settings. The ECHO system includes a mobile application that delivers personalized health insights and alerts, ensuring that workers and their supervisors can take proactive measures to enhance safety and productivity. Incorporated in 2014 and based in New York, Kenzen sells its products through various distributors, resellers, and retail locations, aiming to harness physiological data to improve workforce safety and well-being.

Elemental Machines, Inc., founded in 2014 and based in Cambridge, Massachusetts, specializes in providing a smart lab platform designed to enhance laboratory operations in science-based industries. The company's innovative technology continuously monitors equipment and environmental variables, delivering data-driven insights that foster improved research, development, and manufacturing outcomes. By utilizing intelligent sensors, the platform visualizes the entire testing environment and issues alerts for any anomalous results, thereby ensuring experimental reproducibility. This capability allows clients to refine and accelerate their work across all phases of product innovation, ultimately leading to greater clarity, transparency, and consistency in laboratory processes.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

Kenzen, Inc. is a health technology company that specializes in developing wearable solutions for health and performance monitoring. Its flagship product, the Kenzen ECHO, is a wireless smart patch designed to provide real-time monitoring of vital signs and physiological data, with a focus on preventing injuries related to heat stress, fatigue, and over-exertion in industrial settings. The ECHO system includes a mobile application that delivers personalized health insights and alerts, ensuring that workers and their supervisors can take proactive measures to enhance safety and productivity. Incorporated in 2014 and based in New York, Kenzen sells its products through various distributors, resellers, and retail locations, aiming to harness physiological data to improve workforce safety and well-being.

Somatix Ltd. is a developer of wearable-assisted gesture detection solutions, specializing in real-time remote patient monitoring. Founded in 2015 and headquartered in Ra'anana, Israel, the company employs advanced technology, including adaptive machine learning and predictive analytics, to analyze gesture data passively collected from devices like smartwatches and smartbands. Somatix’s platform detects a variety of physical and emotional indicators, thereby providing valuable clinical insights that assist healthcare providers in managing patient care. Its key offerings include SafeBeing, aimed at elderly patients, and SmokeBeat, which supports smoking cessation efforts. Somatix serves a diverse clientele that includes corporate employers, health insurers, and clinics, all focused on enhancing patient wellbeing and health intervention strategies.

SchoolCare is a digital health platform that provides free health technology to K-12 public schools, enabling school nurses to deliver effective care and enhance student safety. The company aims to create a unified health record for every family by leveraging pediatric health data within the extensive K-12 school system, which serves as a vital public health infrastructure. SchoolCare's platform captures essential student medical information, including charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. By addressing gaps in traditional care coordination, SchoolCare ensures that crucial care instructions reach school nurses, thereby reducing the risk of inconsistent post-discharge care. Through its innovative approach, SchoolCare seeks to improve health outcomes for children and streamline public school health programs across the United States.